Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
On Oct. 13, 2026, AVXL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Anavex Life Sciences Corp. is a small-cap company with a market capitalization of $137M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/B Ratio of 1.08x is the lowest of the 50 peers that report one.
A per-ticker accuracy statistic for AVXL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AVXL included.
Follow AVXL free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
| Metric | AVXL | Rank |
|---|---|---|
| Market Cap | $137M | 60/60 |
| P/B Ratio | 1.08x | 50/50 |
| EPS | $-0.46 | – |
| Book Value/Share | $1.37 | – |
| Metric | AVXL | Rank |
|---|---|---|
| ROE | -27.2% | 19/47 |
| ROA | -25.9% | 24/49 |
| Metric | AVXL | Rank |
|---|---|---|
| D/E Ratio | 0.05x | 48/50 |
| Financial Leverage | 1.05x | 48/50 |
| Interest Coverage | -6.3x | 17/38 |
| Metric | AVXL | Rank |
|---|---|---|
| Operating Cash Flow | -$34M | 19/52 |
| Metric | AVXL | Rank |
|---|---|---|
| Operating Income | -$44M | 15/50 |
| Net Income | -$34M | 15/49 |
| R&D Expense | $32M | 48/51 |
| Metric | AVXL | Rank |
|---|---|---|
| Shares Outstanding | 93M | – |
| Total Liabilities | $6M | 4.8% of assets |
Companies classified under the same SEC industry code as Anavex Life Sciences Corp. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| AVXL Anavex Life Sciences Corp. | ▶ | $137M |
| AMGN Amgen Inc | ▼ | $223.19B |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B |
| MRNA Moderna, Inc. | ▲ | $86.33B |
| ARGX Argenx Se | ▶ | $49.67B |
| RVMD Revolution Medicines, Inc. | ▲ | $41.57B |
| BIIB Biogen Inc. | ▼ | $33.79B |
| BNTX Biontech Se | ▶ | $22.51B |
| MESO Mesoblast Ltd | ▼ | $18.02B |
| EXEL Exelixis, Inc. | ▲ | $14.75B |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.44B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| IBRX Immunitybio, Inc. | ▲ | $10.39B |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B |
| RGEN Repligen Corp | ▲ | $9.90B |
| QGEN Qiagen N.V. | ▼ | $9.86B |
| TWST Twist Bioscience Corp | ▲ | $9.52B |
| KRYS Krystal Biotech, Inc. | ▲ | $9.51B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B |
| IMVT Immunovant, Inc. | ▲ | $5.93B |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.53B |
| SRRK Scholar Rock Holding Corp | ▲ | $5.11B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.94B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.26B |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.15B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.08B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.91B |
| ALVO Alvotech | ▶ | $1.68B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.61B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B |
| IMCR Immunocore Holdings Plc | ▲ | $1.43B |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.35B |
| VOR Vor Biopharma Inc. | ▶ | $1.17B |
| REPL Replimune Group, Inc. | ▲ | $1.14B |
| VALN Valneva Se | ▼ | $1.03B |
| JATT Zura Bio Ltd | ▼ | $1.01B |
| MGTX Meiragtx Holdings Plc | ▶ | $955M |
| IMTX Immatics N.V. | ▶ | $916M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M |
| SANA Sana Biotechnology, Inc. | ▶ | $784M |
| SLDB Solid Biosciences Inc. | ▲ | $719M |
| CADL Candel Therapeutics, Inc. | ▲ | $709M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M |
| AURA Aura Biosciences, Inc. | ▲ | $650M |
| PRME Prime Medicine, Inc. | ▲ | $602M |
Hello, everyone, and thank you for joining us on the call today. Before we begin, let me remind you that we will make forward-looking statements on this call, and actual results may differ materially ...
Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2026 First Quarter Conference Call. My name is Clint Tomlinson. I will be your host for today's call. [Operator Instructions].
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On Oct. 13, 2026, AVXL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
A per-ticker accuracy statistic for AVXL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Anavex Life Sciences Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
60 issuers in our coverage, AVXL included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.